IS20

IS20 is an agonist of prokineticin receptor 1 (PKR1) . It reduces Doxorubicin-induced apoptosis and ROS production by activating the Akt or MAPK pathways. In mouse models, IS20 protects the heart from cardiovascular toxicity caused by Doxorubicin, improving survival rates and cardiac function. It does not alter the cytotoxicity and anti-tumor effects of acute Doxorubicin treatment on breast cancer cells and the MDA-MB-231 xenograft mouse model. IS20 is applicable in cancer research.